Index

Note: Page numbers of article titles are in boldface type.

A
Abscess, gingival/periodontal, oral pain due to, 277–278
Alveolar osteitis, oral pain due to, 278–279
Anesthesia dolorosa, 365
Aphthous stomatitis, recurrent, oral pain due to, 281
Arthritis, temporomandibular, medications for, 417–418, 419
anticytokine therapy for rheumatoid arthritis, 418
corticosteroid injections, 417
NSAIDs, 417
opioids, 418
Arthropathies, causing internal derangement of TMJ, 320–330
false, 327–329
inflammatory/degenerative, 320–325
localized atypical, 326–327
prevalence of each etiologic category, 329–330
systemic, 325–326
Arthroscopy, for internal derangement of TMJ joint, 320–330
Auriculotemporal nerve block, for headache and facial pain, 427–428

B
Behavioral interventions, for TMJ disorders and headache, 341
Behavioral medicine, for chronic orofacial pain, 247–260
cognitive behavioral therapy, 249–253
historical review of, 249–250
styles of distorted thinking, 250–252
tools for, 252–253
mindfulness-based cognitive therapy, 254–259
somatic quieting, 255–258
stress reduction, 258–259
neuroscience of mindfulness behavior, 253–254
somatic focus of, 248–249
Bone pain, intraoral, 284–285
maxillary sinusitis, 284–285
osteomyelitis, 284
osteonecrosis, 284
Botulinum toxin, for TMJ disorders and headache, 342
Bruxism, 403–405

Burning mouth syndrome, 381–396
associated features, 386
psychosocial comorbidities, 386
saliva, 386
taste, 386
causes, 384–386
local factors, 385
psychological factors, 385–386
systemic factors, 385
classification, 382–384
clinical signs and symptoms, 384
diagnosis, 389
diagnostic criteria, 382
epidemiology, 382
management, 389–391
behavioral strategies, 389–391
systemic therapies, 391
topical therapies, 391
pathophysiologic theories, 386–389
hormonal alterations, 387
neuropathic considerations, 387–389
autoimmune disorder (lichen planus), 388–389
central pain related to deficient dopaminergic inhibition, 388
nociceptive channels and neuropeptides, 387–388
peripheral small fiber neuropathy, 387
subclinical trigeminal neuralgia, 388
taste and sensory system interactions, 386–387

C
Cancer therapy, oral mucositis related to, 283
Candidiasis, oral pain due to, 279–280
Caries, intraoral pain due to, 276
Cementum, exposed, intraoral pain due to, 276
Cervical facet nerve blocks, for headache and facial pain, 430
Chronic orofacial pain. See Orofacial pain.
Classification, of orofacial pain, 238–246
ear and throat pain, 244
eye pain, 242, 243, 244
International Headache Society categories, 238–239
masticatory muscle disorders, 240
mucosal conditions, 242
odontogenic pain, 240, 241

Ora1maxsurgery.theclinics.com
http://dx.doi.org/10.1016/S1042-3699(16)30051-6
1042-3699/16/$ – see front matter
Classification (continued)
  salivary gland disease, 242
  TMJ disorders, 240
  trigeminal neuropathic pain disorders, 245
Cognitive behavioral therapy, for chronic orofacial pain, 249–253
  historical review of, 249–250
  styles of distorted thinking, 250–252
  tools for, 252–253
  for painful traumatic trigeminal neuropathy, 375–376
Comorbidity, TMJ disorders and headache, 335–349
Compression theory, in trigeminal neuralgia, 354–355
Cracked tooth syndrome, oral pain due to, 241, 277
Cranial neuralgias, 351–370
  anesthesia dolorosa, 365
  classical, 351–363
  cause and pathophysiology, 352–353
  compression theory, 353–354
  differential diagnosis, 359–360
  epidemiology, 352
  history, 351–352
  light touch to face as trigger for, 358
  paroxysmal pain in, 358
  problems with current theories, 354–359
  Sweet criteria, 357
  symptoms and signs, 356–357
  treatment, 360–363
  for acute attacks, 361
  medication, 360–361
  nerve and neurolytic blockade treatment, 361–362
  surgical, 362–363
  other cranial neuralgias, 364
  other trigeminal branch neuralgias, 364–365
  secondary (painful), 363–364
Cranial neuropathies, painful, International Headache Society classification of, 238–239
Drug-induced extrapyramidal reactions, 401–403
Dry socket. See Alveolar osteitis.
Dyskinesia, orofacial, 400–401
Dystonia, orofacial, 397–400
Ear pain, types of, 244
Extractions, painful traumatic trigeminal neuropathy due to, 372
Extrapyramidal reactions, drug-induced, 401–403
Eye pain, examination of, 243
  headaches and facial pain syndromes with predominant findings of, 244
  ophthalmologic findings, 243
  red flags for patient with, 242
Facial pain. See Orofacial pain.
Fibromyalgia, medications for, 415–417, 419
  behavioral methods vs medications for, 416
  efficacy of, 415–416
  opioids for, 416–417
  pregabalin for, 416
Gabapentinoids, for trigeminal neuropathic pain, 411–412
Gingival abscess, oral pain due to, 277–278
Gingival recession, intraoral pain due to, 276
Glossodynia. See Burning mouth syndrome.
Headache, chronic daily, medications for, 413–415, 419
  efficacy of preventive medications for, 413–414
  naproxen, 413
  opioids, 415
  patient compliance with, 414
  injection therapy for facial pain and, 423–434
  clinical conditions treated with, 424
  contraindications to peripheral nerve blockade, 425
  mechanisms of nerve block effects in, 424–425
  overview of pharmacology, 424
  procedural techniques for nerve blocks, 425–426
  specific nerve blocks, 426–432
  International Headache Society classification of, 238–239
  red flags in history of, 2467
  temporomandibular joint (TMJ) disorders and, 335–349
behavioral interventions, 341
epidemiology of comorbidity of, 336–337
inflammatory joint disorders, 338
management, 339–340
nonsurgical TMJ disorder treatment, 340
patient education, 340
self-care, 340
treating headache by targeting TMJ
disorders, 339–340
muscular pain, 338–339
orthopedic jaw appliances (splints), 341
pathophysiology relationship of, 337
pharmacotherapy, 341–342
botulinum toxin, 342
local anesthetics, 342
muscle relaxants, 342
NSAIDs and corticosteroids, 341–342
physical therapy, 340–341
surgical treatment, 342
TMJ structure and function, 337–338
occlusal adjustment, 343
splint therapy, 343–344
Herpes simplex virus, oral pain due to, 280
Herpes zoster, oral pain due to, 280–281
History, medical, in diagnosis of orofacial pain, 235
Human immunodeficiency virus (HIV), intraoral pain
related to immunocompromised state, 283–284
Imaging, in diagnosis of orofacial pain, 237
Immunocompromised states, intraoral pain related
to, 283–284
Implants, dental, painful traumatic trigeminal
neuropathy due to, 372
removal of due to, 376
Inflammatory joint disorders, TMJ disorders and
headache due to, 338
Infraorbital nerve blocks, for headache and facial
pain, 428–429
Injection therapy, for headache and facial pain, 423–434
clinical conditions treated with, 424
contraindications to peripheral nerve
blockade, 425
mechanisms of nerve block effects in, 424–425
overview of pharmacology, 424
procedural techniques for nerve blocks, 425–426
specific nerve blocks, 426–432
auriculotemporal, 427–428
cervical facet and spinal root, 430
greater occipital, 426–427
infraorbital, 426–429
lesser occipital, 427
onabotulinum toxin injections, 430–432
sphenopalatine ganglion, 429–430
supraorbital and supratrochlear, 428
trigger point injections, 430
Internal derangement. See Temporomandibular joint
(TMJ) disorders.
International Headache Society, classification of
headache disorders, 238–239
Intraoral appliance therapy, for myofascial pain, 304
Intraoral pain disorders, 275–288
dental and pulpal, 275–277
carries, 276
cracked tooth syndrome, 277
exposed cementum or dentin, 276
pulpal disease, 276–277
oral bone pain, 284–285
maxillary sinusitis, 284–285
osteomyelitis, 284
osteonecrosis, 284
oral mucosal pain, 279–284
candidiasis, 279–280
herpes simplex virus, 280
herpes zoster (shingles), 280–281
in immunocompromised states, 283–284
lichen planus, 282
necrotizing periodontal diseases, 281
oral mucositis related to cancer therapy, 283
recurrent aphthous stomatitis, 281
squamous cell carcinoma, 282–283
vesiculobullous diseases, 282
periodontal, 277–279
alveolar osteitis, 278–279
gingival/periodontal abscess, 277–278
periapical inflammatory lesions, 278
pericoritis, 279
salivary gland abnormalities, 285–287
bacterial sialadenitis, 285–286
mumps, 286
neoplasms, 286–287
oral sialoliths, 285
Sjogren’s syndrome, 286
Juvenile idiopathic arthritis. See Arthritis.
Lichen planus, oral pain due to, 282
Local anesthetics, painful traumatic trigeminal
neuropathy due to, 373
for TMJ disorders and headache, 342
Mandibular third molar extractions, painful traumatic
trigeminal neuropathy due to, 372
Masticatory muscle disorders, types of, 240
Maxillary sinusitis, intraoral pain related to, 284–285
Medications. See also specific drugs.
treatment efficacy for chronic orofacial pain, 409–421
for chronic daily headaches, 413–415, 419
for chronic myofascial pain/fibromyalgia, 415–417, 419
for temporomandibular arthritis, 417–418, 419
for trigeminal neuropathic pain, 410–413, 419
Migraine, chronic, medications for, 413–415, 419
efficacy of preventive medications for, 413–414
naproxen for episodic, 413
opioids, 415
patient compliance with, 414
International Headache Society classification of, 238–239
Migraine. See also Headache.
pathophysiology of relationship between TMJ disorders and, 337
Mindfulness-based cognitive therapy, for chronic orofacial pain, 254–259
somatic quieting, 255–258
stress reduction, 258–259
Movement disorders, orofacial, 397–407
bruxism, 403–405
drug-induced extrapyramidal reactions, 401–403
orofacial dyskinesia, 400–401
orofacial dystonia, 397–400
Mucosal pain, common types of, 242
oral, 279–284
candidiasis, 279–280
herpes simplex virus, 280
herpes zoster (shingles), 280–281
in immunocompromised states, 283–284
lichen planus, 282
necrotizing periodontal diseases, 281
oral mucositis related to cancer therapy, 283
recurrent aphthous stomatitis, 281
squamous cell carcinoma, 282–283
vesiculobullous diseases, 282
Mumps, oral pain related to, 286
Muscle relaxants, for TMJ disorders and headache, 342
Muscles. See Myofascial pain.
Myofascial pain, 289–311
cause and pathology, 296–299
activation of muscle nociceptors, 297–299
central biasing of nociceptive input, 299
CNS changes, 299
injury to muscle fiber type 1, 297
metabolic distress at the motor end plates, 297
peripheral and central sensitization, 296
peripheral changes, 296–297
clinical presentation, 290–296
association with other pain conditions, 292–293
clinical characteristics, 290–292
contributing factors, 295–296
examination findings, 293–295
pain symptoms, 295
relationship to other muscle pain disorders, 293
evidence-based management, 299–307
determine a complete problem list, 300
health care provider as agent of change, 302
interdisciplinary team management, 305–307
intraoral appliance therapy, 304
match complexity of management and patient, 300
muscle exercises, 302–303
muscle treatments, 303–304
pharmacotherapy, 304–305
training to reduce risk factors, 305
transformative care model, 300–302
most common conditions, 290
N
Naproxen, for chronic daily headache, 413
Necrotizing periodontal diseases, oral pain due to, 281
Nerve blocks. See also Injection therapy.
for headache and facial pain, 426–432
auriculotemporal, 427–428
cervical facet and spinal root, 430
greater occipital, 426–427
infraorbital, 428–429
lesser occipital, 427
onabotulinum toxin injections, 430–432
sphenopalatine ganglion, 429–430
supraorbital and supratrochlear, 428
trigger point injections, 430
Neuralgia. See Cranial neuralgias and Trigeminal neuralgia.
Neuropathic pain. See Trigeminal neuropathy.
Neuroscience, of mindfulness behavior, 253–254
Nonsteroidal anti-inflammatory drugs (NSAIDs), for TMJ disorders and headache, 341–342
O
Odontogenic pain, differential diagnosis of, 240–241
cracked tooth, 241
dentinal, 241
periodontal, 241
pulpitis, 241
features of, 240
Onabotulinum toxin, nerve block with, for headache and facial pain, 430–432
Opioid risk stratification, model for, in patients with chronic orofacial pain, 261–273
cranial neuralgias, anesthesia dolorosa, 365
  classical, 351–363
  other cranial neuralgias, 364
  other trigeminal branch neuralgias, 364–365
  secondary (painful), 363–364
injection therapy for headache and, 423–434
  clinical conditions treated with, 424
  contraindications to peripheral nerve
  blockade, 425
  mechanisms of nerve block effects in, 424–425
  overview of pharmacology, 424
  procedural techniques for nerve blocks,
  425–426
  specific nerve blocks, 426–432
internal derangement of TMJ, 313–333
  current classification systems of TMJ
  disorders, 314–316
  definition from an orthopaedic
  perspective, 316
  is it a disease, 316–317
  is treatment required, 317–320
  management based on disease cause,
  320–330
intraoral pain disorders, 275–288
  dental and pulpal, 275–277
  oral bone pain, 284–285
  oral mucosal pain, 279–284
  periodontal, 277–279
  salivary gland abnormalities, 285–287
medication treatment efficacy for chronic,
  409–421
  for chronic daily headaches, 413–415, 419
  for chronic myofascial pain/fibromyalgia,
  415–417, 419
  for temporomandibular arthritis, 417–418, 419
  for trigeminal neuropathic pain, 410–413, 419
model for opioid risk stratification,
  261–273
  risk assessment and patient management,
  264–270
  counseling the patient, 268–270
  cross-communication with medical and
dental providers and others, 266–267
  prescription monitoring programs, 265–266
  risk-screening questionnaires for opioid
  therapy, 267–268
  special at-risk populations, 270–271
  substance use disorders, 263–264
Opioids, for chronic migraine and chronic daily
  headache, 415
  for fibromyalgia, 416–417
  for temporomandibular arthritis, 418
  for trigeminal neuropathic pain, 412–413
Orofacial pain, 233–434
  behavioral medicine and chronic, 247–260
  cognitive behavioral therapy, 249–253
  historical review of, 249–250
  styles of distorted thinking, 250–252
  tools for, 252–253
  mindfulness-based cognitive therapy, 254–259
    somatic quieting, 255–258
    stress reduction, 258–259
  neuroscience of mindfulness behavior,
    253–254
  somatic focus of, 248–249
burning mouth syndrome, 381–396
  associated features, 386
  causes, 384–386
  classification, 382–384
  clinical signs and symptoms, 384
  diagnosis, 389
  diagnostic criteria, 382
  epidemiology, 382
  management, 389–391
  pathophysiologic theories, 386–389
classification and differential diagnosis, 233–246
  classification, 238–246
    ear and throat pain, 244
    eye pain, 242, 243, 244
  International Headache Society categories,
    238–239
  masticatory muscle disorders, 240
  mucosal conditions, 242
  odontogenic pain, 240, 241
  salivary gland disease, 242
  TMJ disorders, 240
  trigeminal neuropathic pain disorders, 245
diagnostic evaluation, 234–238
  chief complaint, 235
  history of present complaint, 235
  imaging, 237
  medical history, 235
  other studies, 237
  physical examination, 235–237
  psychosocial evaluation, 237
risk assessment and patient management,
  264–270
  counseling the patient, 268–270
  cross-communication with medical and
dental providers and others, 266–267
  prescription monitoring programs, 265–266
  risk-screening questionnaires for opioid
  therapy, 267–268
  special at-risk populations, 270–271
  substance use disorders, 263–264
Opioids, for chronic migraine and chronic daily
  headache, 415
  for fibromyalgia, 416–417
  for temporomandibular arthritis, 418
  for trigeminal neuropathic pain, 412–413
Orofacial pain, 233–434
  behavioral medicine and chronic, 247–260
  cognitive behavioral therapy, 249–253
  historical review of, 249–250
  styles of distorted thinking, 250–252
  tools for, 252–253
  mindfulness-based cognitive therapy, 254–259
    somatic quieting, 255–258
    stress reduction, 258–259
  neuroscience of mindfulness behavior,
    253–254
  somatic focus of, 248–249
burning mouth syndrome, 381–396
  associated features, 386
  causes, 384–386
  classification, 382–384
  clinical signs and symptoms, 384
  diagnosis, 389
  diagnostic criteria, 382
  epidemiology, 382
  management, 389–391
  pathophysiologic theories, 386–389
classification and differential diagnosis, 233–246
  classification, 238–246
    ear and throat pain, 244
    eye pain, 242, 243, 244
  International Headache Society categories,
    238–239
  masticatory muscle disorders, 240
  mucosal conditions, 242
  odontogenic pain, 240, 241
  salivary gland disease, 242
  TMJ disorders, 240
  trigeminal neuropathic pain disorders, 245
diagnostic evaluation, 234–238
  chief complaint, 235
  history of present complaint, 235
  imaging, 237
  medical history, 235
  other studies, 237
  physical examination, 235–237
  psychosocial evaluation, 237
Orofacial (continued)
orofacial dystonia, 397–400
painful traumatic trigeminal neuropathy, 371–380
assessing and diagnosing, 373–374
causes of, 372–373
dental implants, 372
local anesthetic injections, 373
macrotrauma, 372
mandibular third molars, 372
root canal therapy, 372–373
clinical features of, 373
management of, 375–377
central surgery, 376–377
cognitive behavioral therapy, 375–376
controlling associated inflammation, 376
pharmacotherapy, 375
removing offending implants, 376
surgery, 376
pathophysiology of, 374–375
prevalence, 372
prevention of, 375
temporomandibular disorders and headache, 335–349
behavioral interventions, 341
epidemiology of comorbidity of, 336–337
inflammatory joint disorders, 338
management, 339–340
muscular pain, 338–339
orthopedic jaw appliances (splints), 341
pathophysiology relationship of, 337
pharmacotherapy, 341–342
physical therapy, 340–341
surgical treatment, 342
TMJ structure and function, 337–338
treatments not proven helpful or effective, 342–344
Osteoarthritis. See Arthritis.
Osteomyelitis, intraoral pain related to, 284
Osteonecrosis, intraoral pain related to, 284

P
Pain, orofacial. See Orofacial pain.
Physiologic trauma trigeminal neuropathy. See
Trigeminal neuropathy.
Periapical inflammatory lesions, oral pain due to, 278
Pericoronitis, oral pain due to, 279
Periodontal abscess, oral pain due to, 277–278
Periodontal issues, in differential diagnosis of
odontogenic pain, 241
Periodontal pain, 277–279
alveolar osteitis, 278–279
gingival/periodontal abscess, 277–278
periapical inflammatory lesions, 278
pericoronitis, 279
Peripheral nerve blockade, for headache and facial
pain, 423–434
clinical conditions treated with, 424
contraindications to peripheral nerve
blockade, 425
mechanisms of nerve block effects in, 424–425
overview of pharmacology, 424
procedural techniques for nerve blocks, 425–426
specific nerve blocks, 426–432
Physical examination, in diagnosis of orofacial pain, 235–237
Physical therapy, for TMJ disorders and headache, 340–341
Pregabalin, for fibromyalgia, 416
Preventive medications, efficacy of, for chronic daily
headache, 413–414
Psychosocial components, of orofacial pain, in model
for opioid risk stratification, 261–273
Psychosocial evaluation, in diagnosis of orofacial
pain, 237
Pulpal disease, intraoral pain due to, 276–277
Pulpitis, in differential diagnosis of odontogenic
pain, 241

R
Rheumatoid arthritis. See also Arthritis.
temporomandibular, anticytokine therapy for, 418
Risk management, for opioid treatment of chronic
orofacial pain, 261–273
risk assessment and patient management, 264–270
counseling the patient, 268–270
cross-communication with medical and
dental providers and others, 266–267
prescription monitoring programs, 265–266
risk-screening questionnaires for opioid
therapy, 267–268
special at-risk populations, 270–271
substance use disorders, 263–264
Root canal therapy, painful traumatic trigeminal
neuropathy due to, 372–373

S
Salivary gland abnormalities, intraoral pain due to, 285–287
bacterial sialadenitis, 285–286
mumps, 286
neoplasms, 286–287
oral sialoliths, 285
Sjogren’s syndrome, 286
Salivary gland disease, types of, 242
Secondary trigeminal neuralgia, 363–364
Serotonin-norepinephrine reuptake inhibitors, for
trigeminal neuropathic pain, 411–412
Shingles. See Herpes zoster.
Sialadenitis, bacterial, oral pain related to, 285–286
Sialoliths, oral, pain related to, 285
Sinusitis, maxillary, intraoral pain related to, 284–285
Sjogren’s syndrome, oral pain related to, 286
Somatic quieting, for relief of chronic orofacial pain, 255–258
Sphenopalatine ganglion injections, for headache and facial pain, 429–430
Spinal root nerve blocks, for headache and facial pain, 430
Splints, for TMJ disorders and headache, 341
Squamous cell carcinoma, oral pain due to, 282–283
Stress reduction, for relief of chronic orofacial pain, 258–259
Substance abuse disorders, model for opioid risk management in chronic orofacial pain, 261–273
Supraorbital nerve blocks, for headache and facial pain, 428
Supratrochlear nerve blocks, for headache and facial pain, 428
Tardive dyskinesia, 400–401
Temporomandibular joint (TMJ) disorders, and headache, 335–349
behavioral interventions, 341
epidemiology of comorbidity of, 336–337
inflammatory joint disorders, 338
management, 339–340
nonsurgical TMJ disorder treatment, 340
patient education, 340
self-care, 340
treating headache by targeting TMJ disorders, 339–340
muscular pain, 338–339
orthopedic jaw appliances (splints), 341
pathophysiology relationship of, 337
pharmacotherapy, 341–342
botulinum toxin, 342
local anesthetics, 342
muscle relaxants, 342
NSAIDs and corticosteroids, 341–342
physical therapy, 340–341
surgical treatment, 342
TMJ structure and function, 337–338
treatments not proven helpful or effective, 342–344
occlusal adjustment, 343
splint therapy, 343–344
internal derangement, 313–333
current classification systems of TMJ disorders, 314–316
definition from an orthopaedic perspective, 316
is it a disease, 316–317
is treatment required, 317–320
clinical research results, 318–319
historical perspective, 317–318
surgical outcomes, 319–320
management based on disease cause, 320–330
false arthropathy, 327–329
inflammatory/degenerative arthropathy, 320–325
localized atypical arthropathy, 326–327
prevalence of each etiologic category, 329–330
systemic arthropathy, 325–326
types of, 240
Throat pain, types of, 244
Transplantation, intraoral pain related to immunocompromised state, 283–284
Traumatic trigeminal neuropathy. See Trigeminal neuropathy.
Tricyclic antidepressants, for trigeminal neuropathic pain, 412
Trigeminal neuralgia, 351–370
anesthesia dolorosa, 365
classical, 351–363
cause and pathophysiology, 352–353
compression theory, 353–354
differential diagnosis, 359–360
epidemiology, 352
history, 351–352
light touch to face as trigger for, 358
paroxysmal pain in, 358
problems with current theories, 354–359
Sweet criteria, 357
symptoms and signs, 356–357
treatment, 360–363
for acute attacks, 361
medication, 360–361
nerve and neurolytic blockade treatment, 361–362
surgical, 362–363
International Headache Society classification of, 238–239
other cranial neuralgias, 364
other trigeminal branch neuralgias, 364–365
secondary (painful), 363–364
Trigeminal neuropathic pain, diagnosis and treatment of, 245
medications for, 410–413, 419
gabapentinoids and serotonin-norepinephrine reuptake inhibitors, 411–412
opioids, 412–413
topical, 410–411
tricyclic antidepressants, 412
Trigeminal neuropathy, painful traumatic, 371–380
assessing and diagnosing, 373–374
causes of, 372–373
dental implants, 372
local anesthetic injections, 373
macrotrauma, 372
Trigeminal (continued)
  mandibular third molars, 372
  root canal therapy, 372–373
  clinical features of, 373
  management of, 375–377
    central surgery, 376–377
    cognitive behavioral therapy, 375–376
    controlling associated inflammation, 376
    pharmacotherapy, 375
    removing offending implants, 376
  pathophysiology of, 374–375
  central sensitization, 374–375
  nerve injury and ectopic activity, 374
  novel sensitivity to catecholamines, 374
  peripheral sensitization, 374
  phenotypic changes, 374
  Trigger point injections, for headache and facial pain, 430

V
  Vesiculobullous disease, oral pain due to, 282